Results 21 to 30 of about 339,213 (296)

Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Frontiers in Pharmacology, 2021
The development of antibody-drug conjugates (ADCs) has significantly been advanced in the past decade given the improvement of payloads, linkers and conjugation methods.
Dian Su, Donglu Zhang
semanticscholar   +1 more source

Resistance to Antibody–Drug Conjugates [PDF]

Cancer Research, 2018
Abstract Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent.
García-Alonso, Sara, Ocaña, Alberto, Pandiella, Atanasio   +2 more
openaire   +4 more sources

An Immunosuppressive Antibody–Drug Conjugate [PDF]

Journal of the American Chemical Society, 2015
We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E, Liu, Tao, Wang, Ying, Cao, Yu, Du, Jintang, Luo, Xiaozhou, Deshmukh, Vishal, Kim, Chan Hyuk, Lawson, Brian R, Tremblay, Matthew S, Young, Travis S, Kazane, Stephanie A, Wang, Feng, Schultz, Peter G   +13 more
openaire   +6 more sources

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Cancer Research, 2021
These findings show that targeting AXL-positive tumor fractions with an antibody–drug conjugate enhances anti-tumor immunity in several humanized tumor models of melanoma and lung cancer.
J. Boshuizen, N. Pencheva, O. Krijgsman, Daniela D’Empaire Altimari, P. G. Castro, Beaunelle de Bruijn, M. Ligtenberg, Elke Gresnigt-van den Heuvel, David W. Vredevoogd, Ji-Ying Song, Nils L. Visser, Georgi Apriamashvili, M. Janmaat, T. Plantinga, P. Franken, M. Houtkamp, A. Lingnau, M. Jure-Kunkel, D. Peeper   +18 more
semanticscholar   +1 more source

A Vaccine Against Group B Streptococcus: Recent Advances [PDF]

, 2020
Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World ...
Carreras-Abad, C, Heath, PT, Le Doare, K, Ramkhelawon, L   +3 more
core   +2 more sources

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Cancer Medicine, 2021
Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy.
Wen-Qian Li, Han-Fei Guo, Lingyu Li, Yong-fei Zhang, J. Cui   +4 more
semanticscholar   +1 more source

Antibody–Drug Conjugates—A Tutorial Review [PDF]

Molecules, 2021
Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small-molecule payloads and two with biological toxins) approved for use by the FDA.
Stephanie Baah, Mark Laws, Khondaker Miraz Rahman   +2 more
openaire   +5 more sources

Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. [PDF]

, 2014
Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival.
Bonavida, Benjamin, Shvartsur, Anna
core   +5 more sources

Antibody–Drug Conjugates for Cancer Therapy [PDF]

Molecules, 2020
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows ...
Sagun Parakh, Sagun Parakh, Umbreen Hafeez, Umbreen Hafeez, Andrew M. Scott, Hui K Gan   +5 more
openaire   +4 more sources

Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. [PDF]

, 2019
Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and ...
Cui, Xianshu, Dowdy, Steven F, Huggins, Ian J, Jadhav, Satish, Medina, Carlos A, Springer, Aaron D, van den Berg, Arjen   +6 more
core   +1 more source